Tuesday, April 28, 2026, 12:00 PM–1:00 PM ET
Discover how next-day comprehensive genomic profiling (CGP) is possible with the Oncomine Comprehensive Assay Plus on the Genexus System—delivering both speed and accuracy.
Webinar presenters Jane Bayani, MHSc, PhD, Assistant Professor and Co-Director, Diagnostic Development, Ontario Institute for Cancer Research, Canada, and Nicola Normanno, MD, Scientific Director, IRCCS Romagnolo Institute for the Study of Tumors, Italy, and Morten Grauslund, PhD, Molecular Biologist, Department of Pathology, Rigshospitalet/Copenhagen University Hospital, Copenhagen, Denmark.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Thermo Fisher Scientific. For Research Use Only. Not for use in diagnostic applications.
Thursday, April 30, 2026, 11:00 AM–12:00 PM ET
Hear an expert discuss how Memorial Sloan Kettering Cancer Center (MSKCC) is utilizing
the oncoReveal® Nexus 21-gene panel to redefine turnaround time and actionable insights
in cancer care. Dr. Ewalt shares a perceptive look at the clinical need for rapid, front-line NGS sequencing, and how a unique, purpose built targeted NGS panel (Pillar Biosciences’ oncoReveal Nexus 21 gene Panel) was developed, validated and implemented clinically by Memorial Sloan Kettering Cancer Center (MSK-REACT) to complement their current comprehensive genomic profiling (CGP) approach.
Webinar presenter Mark Ewalt, MD, Associate Medical Director for Laboratory Operations for Diagnostic Molecular Pathology in the Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, MSKCC.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Pillar Biosciences.
Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.
Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy, CEO of mTuitive.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
October 2017—BioMérieux announced that BacT/Alert Virtuo, its fully automated blood culture system, has received 510(k) clearance from the FDA and is commercially available in the United States and in countries that recognize the CE mark.
October 2017—Beckman Coulter Diagnostics and partner Diazyme Laboratories announced FDA clearance of a new procalcitonin (PCT) assay for the management of bacterial infections and sepsis.
October 2017—Formulatrix announced the release of its next-generation Constellation Digital PCR System. The digital PCR system mimics contemporary qPCR with a plate-based and high-throughput workflow capable of processing up to four plates per run. For higher throughput applications such as gene expression analysis, plates that accommodate 96 samples will provide partitioning into 8,000 microfluidic chambers per sample.
October 2017—Aim Lab Automation Technologies unveiled at the AACC annual meeting the PathFinder 350D, the latest PathFinder automation platform for decapping and sorting incoming blood collection tubes directly into various analyzer racks ready for analysis.
October 2017—Biocartis Group announced the availability of its Idylla platform in the United States. The Idylla is a fully automated, walkaway, real-time PCR system with a hands-on time of less than two minutes. Its access on-demand design and assay turnaround time of between 90 and 150 minutes allow pathologists to analyze samples at any time, without the need for batching or for trained operators, in virtually any laboratory. The Idylla console and instrument are class II exempt.
October 2017—Siemens Healthineers announced a strategic relationship with Fast-track Diagnostics that includes the addition of FTD’s broad range of CE-marked kits and multisyndromic panels to the menu of Siemens’ Versant kPCR Molecular System.
October 2017—Quidel announced a revised definitive agreement with Alere for its pending acquisition of Alere’s B-type Natriuretic Peptide assay business run on Beckman Coulter analyzers under which post-acquisition, Quidel will undertake direct commercial responsibility for all BNP sales worldwide.
October 2017—The U.S. Preventive Services Task Force posted on Sept. 12 a draft recommendation statement and draft evidence review on screening for cervical cancer. The task force recommends that primary care clinicians screen for cervical cancer in women who are 21–29 years old every three years with cervical cytology. For women ages 30 to 65, screening is recommended with either cervical cytology alone every three years or with high-risk human papilloma virus (hrHPV) testing alone every five years.
September 2017—Siemens Healthineers showcased its Atellica Solution, flexible, scalable, automation-ready immunoassay and chemistry analyzers for laboratory diagnostics, at the 69th AACC Annual Scientific Meeting and Clinical Lab Expo. The 510(k)-cleared Atellica Solution, for mid- and high-volume labs, comprises sample management and immunoassay and chemistry analyzer components.
September 2017—LGC Maine Standards’ Validate D-Dimer linearity and calibration verification test kit has received FDA 510(k) clearance for use on Siemens Sysmex CS-2500 System analyzers.
